EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide

Hamlet Gasoyan iD, Rebecca Schulte, Christopher B Boyer, Nicholas J Casacchia, W Scott Butsch, Phuc Le, Ali Aminian iD, Marcio L Griebeler, Bartolome Burguera, Michael B Rothberg

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Hamlet Gasoyan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptides, Anti-Obesity Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cleveland Clinic - Jack, Joseph and Morton Mandel Accelerator Grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To describe obesity treatments in real‐world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post‐discontinuation. Materials and Methods This retrospective cohort study used electronic health records from 1 January 2021, to 30 June 2025, in a large health system in Ohio and Florida. Adults with overweight or obesity who initiated injectable semaglutide or tirzepatide for obesity or T2D between 2021 and 2023 and discontinued the medication within 3–12 months were included. Main outcomes were reinitiation of the index medication or receipt of an alternative treatment, body weight changes from baseline to index medication discontinuation and from discontinuation to 1‐year post discontinuation.

Results

A total of 7938 patients (mean [SD] age, 55.7 [13.4] years; 5061 [63.8%] female) were identified. During 1‐year post‐discontinuation, 19.6% restarted the index medication and 35.2% received an alternative obesity treatment, including starting another medication (27.4%), lifestyle modification visit (13.7%) and metabolic and bariatric surgery (0.6%). Mean percentage weight change from baseline to discontinuation was −8.4% [95% CI, −8.7%, −8.1%] when treating obesity and −4.4% [95% CI, −4.7%, −4.2%] when treating T2D. Mean percentage weight change from discontinuation to 1 year later was 0.5% [95% CI, 0.0%, 1.0%] when treating obesity and −1.3% [95% CI, −1.6%, −1.0%] when treating T2D; however, there was considerable individual‐level variability.

Conclusion

In this large sample of patients who discontinued semaglutide or tirzepatide, reinitiation of the original medication or receipt of alternative obesity treatment was common. The average weight change 1‐year post‐discontinuation was relatively small; however, there was considerable individual‐level variability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityGlucagon-Like PeptidesAnti-Obesity AgentsHumansSemaglutideTirzepatideFemaleRetrospective StudiesMiddle AgedMaleWeight LossAgedAdultFloridaOhioDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

glucagon‐like peptide‐1 receptor agonistlifestyle modificationlong‐term weight outcomesmetabolic and bariatric surgeryobesity pharmacotherapytreatment discontinuation

Substanzen

SemaglutideTirzepatideGlucagon-Like PeptidesAnti-Obesity Agents

Autor:innen und Institutionen

  • Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Surgery, Bariatric and Metabolic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Endocrinology and Metabolism Department, Medical Specialty Institute, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Hamlet Gasoyan, Ali Aminian

Förderung

  • Cleveland Clinic - Jack, Joseph and Morton Mandel Accelerator Grants

Zitieren

APA

Gasoyan, H., Schulte, R., Boyer, C. B., Casacchia, N. J., Butsch, W. S., Le, P., Aminian, A., Griebeler, M. L., Burguera, B., & Rothberg, M. B. (2026). Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70660

Vancouver

Gasoyan H, Schulte R, Boyer CB, Casacchia NJ, Butsch WS, Le P, et al. Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70660

BibTeX
@article{Gasoyan2026,
  author = {Gasoyan, Hamlet and Schulte, Rebecca and Boyer, Christopher B and Casacchia, Nicholas J and Butsch, W Scott and Le, Phuc and Aminian, Ali and Griebeler, Marcio L and Burguera, Bartolome and Rothberg, Michael B},
  title = {Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70660}
}
Kostenlos starten →